Perspective Therapeutics, Inc. quarterly report, Q2 FY2020

Filing identity and reporting period

Important mismatch: The supplied filing is for Isoray, Inc., not Perspective Therapeutics, Inc. It is a Form 10-Q for the quarter ended December 31, 2019 (Isoray fiscal Q2 2020), with six-month results compared with the six months ended December 31, 2018.

Business context and financial performance

Isoray manufactures and sells Cesium-131 brachytherapy seeds for cancer treatment. Prostate brachytherapy represented 89% of revenue in both the quarter and six-month period.

Six-month operating cash use was $1.931m, versus $2.726m a year earlier. Investing cash use was $0.204m; financing cash use was $0.011m. Cash and cash equivalents were $3.180m at December 31, 2019, down from $5.326m at June 30, 2019. Working capital was $4.291m and the current ratio was 4.20. The company reported no long-term debt. Total liabilities included $1.118m of lease liabilities.

Material changes versus prior periods

• Quarterly sales rose 16%; six-month sales rose 30%. Management attributed growth to new customer accounts, higher orders from existing customers, and a limited contribution from the Blu Build loader.
• Six-month gross profit increased 82%, with gross margin rising to 52% from 37%. The filing attributes the improvement to sales growth, lower isotope unit costs, fixed-cost leverage, and more efficient isotope use.
• Six-month operating loss narrowed to $1.739m from $2.947m. Proprietary R&D declined, while sales and marketing expense increased 10% and general and administrative expense increased 5%.
• Cash declined by $2.146m over the six months. The filing cites operating losses and working-capital movements, including higher prepaid expenses and lower accounts payable.
• Adoption of lease accounting added a right-of-use asset and lease liability of approximately $1.2m. A lease extension also reduced the asset retirement obligation and generated a $73,000 gain in the six-month period.

Outlook, risks, and unusual items

• No formal revenue or earnings guidance is provided. Management said it exceeded its 25% fiscal 2020 revenue-growth target through the first six months and expected cash-flow break-even in three to four years if the targeted growth continued and no extraordinary expenses arose; management cautioned that continued growth is not assured.
• Management said cash reserves were sufficient to fund operations through the remainder of calendar 2020. It also stated future funding may require equity, strategic collaborations, debt, or other potentially dilutive sources, and that any equity financing could be priced at a discount.
• The company anticipated stockholders’ equity could fall below $6m for the quarter ending March 31, 2020, and warned it might need to raise capital within three to six months to maintain its NYSE American listing.
• Customer concentration is significant: approximately 40% of six-month revenue came from three customers, including approximately 24% from one customer. The filing warns losing any of these customers could materially affect revenue.
• Cesium-131 supply depends on Russian sources. One historical reactor remained shut down in 2020 for an indeterminate period; the company reported no Cesium-131 deliveries under its Medikor agreement in the quarter and 31 curies during the six months. Supply continuity and the agreement’s remaining output are uncertain.
• The Blu Build loader’s broader release timing and expected contribution are uncertain. Other treatment applications face variable demand and reimbursement uncertainty. GammaTile sales to GT Medical Technologies were nominal in the reported periods; the FDA expanded the indication in January 2020, after the quarter.
• Management has completed design work for a future production and administration facility but has not decided when or whether to build it. It expected approximately $30,000 of additional production-automation investment over the following three months.

Most important facts for investors to verify

1. Confirm the issuer: the filing is for Isoray, Inc., not Perspective Therapeutics, Inc.
2. Assess cash runway, operating cash burn, and the potential need for dilutive financing or capital to retain the NYSE American listing.
3. Evaluate customer concentration and the durability of prostate brachytherapy growth and gross-margin improvement.
4. Verify Cesium-131 supply availability, including Russian reactor status and progress under supply agreements.
5. Track the broader Blu Build launch, GammaTile commercialization, reimbursement developments, and the timing and funding of any new facility.